For patients with advanced liver fibrosis, change in fibrosis score is by far the most sensitive predictor of progression of non-alcoholic steatohepatitis, according to an analysis of complications among patients participating in two treatment trials. Although the trials were negative for the therapy tested—the monoclonal antibody simtuzumab (Gilead)—they provided an opportunity to evaluate progression through a protocol that captured and then followed baseline variables over